# UbiVac

Source: https://onco.cc/companies/ubivac/  
OnCo record `ubivac` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

UbiVac is developing an off-the-shelf cancer vaccine aimed at proteins made from non-coding regions of the genome, with RNA sequencing to check a patient's tumour expresses the targets, and early data in head and neck cancer.

## Summary

UbiVac's vaccine targets proteins derived from non-coding genome regions that tumours express, screened per patient by RNA sequencing; Future of Cancer Care Today describes it as clinical-stage with good data in head and neck cancer, accessible through trial enrolment.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Tags: ctgov-sponsor; fcct-directory
- HQ: United States (city not published)
- Type: biotech
- Website: https://www.ubivac.com/

## Sources

- Official website: https://www.ubivac.com/
- Listed on Future of Cancer Care Today (Sijbrandij Foundation): https://sijbrandijfoundation.org/fcct

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- technologies: [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/)

---
JSON: https://onco.cc/api/v1/entities/ubivac.json